
Biogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024
Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in…












